Christopher Smith, MD
Allergy · Horseheads, NYNPI 1679675995
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $514,401 of the $622,426 with a category attached, or 82.6%. 35 manufacturers reported payments, led by AstraZeneca at 48.2% of the total. Among allergy clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,599 payments — averaging $389.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$300K
- Sanofi$135K
- GSK$81K
- Regeneron Healthcare Solutions, Inc.$37K
- Pharming Healthcare, Inc.$20K
- Amgen$12K
- plus $37K from 29 others
Across 928 payments — averaging $18,674 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10.6M
- Modernatx, Inc.$3.1M
- Merck$2.3M
- Bavarian Nordic A/s$524K
- LEO Pharma AS$298K
- AstraZeneca$237K
- plus $216K from 7 others
What the payments were for
- Consulting fees$25,9194%
- Speaking & faculty fees$514,40183%
- Travel & lodging$48,1118%
- Food & beverage$33,7995%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 501 | $299,701 |
| Sanofi | 175 | $135,192 |
| GSK | 205 | $81,495 |
| Regeneron Healthcare Solutions, Inc. | 110 | $37,024 |
| Pharming Healthcare, Inc. | 26 | $20,285 |
| Amgen(2 entities) | 52 | $12,188 |
| Genentech USA, Inc. | 27 | $8,880 |
| Genentech, Inc. | 6 | $6,792 |
| Shire North American Group Inc | 19 | $5,604 |
| Merck | 28 | $3,272 |
| Grifols USA, LLC | 43 | $3,168 |
| Novartis | 56 | $1,939 |
| Pfizer | 75 | $1,355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $1,245 |
| Boehringer Ingelheim | 35 | $659 |
| Optinose US, Inc. | 31 | $543 |
| CSL Behring | 24 | $498 |
| Biocryst US Sales Co., LLC | 19 | $432 |
| Teva Pharmaceuticals USA, Inc. | 41 | $406 |
| Regeneron | 3 | $327 |
| Octapharma USA, Inc. | 13 | $295 |
| Alk-abello, Inc | 12 | $197 |
| AbbVie | 8 | $184 |
| Blueprint Medicines Corporation | 6 | $175 |
| Aimmune Therapeutics, Inc. | 8 | $149 |
| ADMA Biomanufacturing LLC | 6 | $129 |
| Kaleo, Inc. | 4 | $68 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $64 |
| Lilly USA, LLC | 2 | $51 |
| EMD Serono, Inc. | 1 | $26 |
| GC Biopharma USA, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Bio Products Laboratory USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$622,426 in reported general payments places this provider in the 95th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 11 | $485,006 |
| Dupixent PenDupilumab | 67 | $276,508 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 33 | $130,409 |
| XolairOmalizumab | 50 | $129,617 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $123,628 |
| Dupixent SyringeDupilumab | 19 | $89,380 |
| Breo ElliptaFluticasone/Vilanterol | 115 | $59,086 |
| NucalaMepolizumab | 14 | $45,414 |
| IcatibantIcatibant Acetate | 14 | $31,964 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $22,708 |
| QnaslBeclomethasone Dipropionate | 27 | $16,336 |
| XhanceFluticasone Propionate | 19 | $13,980 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $12,901 |
| DuleraMometasone/Formoterol | 22 | $10,420 |
| Mometasone Furoate | 130 | $8,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $432 | $485,00611 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala | $81,495 | $228,128274 claims |
| CSL BehringHizentra | $498 | $130,40933 claims |
| Genentech, Inc.Xolair | $6,792 | $129,61750 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl, Qvar Redihaler | $406 | $24,17140 claims |
| AstraZenecaBreztri Aerosphere | $299,701 | $22,70832 claims |
| Optinose US, Inc.Xhance | $543 | $13,98019 claims |
| MerckDulera | $3,272 | $10,42022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 allergy providers in New York.
Other allergy in Horseheads
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
- Alissa McInerneyAstoria$38K
- Audrey WeissmanElmhurst$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.